Webcast regarding Probi’s acquisition of Nutraceutix

The information in this press release is not intended for distribution, publication or public release, directly or indirectly, in or into Australia, Canada, Japan, the United States or any other jurisdiction where the distribution of this press release may be unlawful.

Probi AB (publ) (“Probi”) announced yesterday that its US subsidiary Probi USA, Inc. has signed an asset purchase agreement under which Probi will acquire the operations of the US probiotic company TNTGamble, Inc., doing business as Nutraceutix, (“Nutraceutix”).

A webcast with teleconference including Q&A will be held today, June 7, 2016, at 10:00 a.m. Participants from Probi: Peter Nählstedt, CEO and Niklas Brandt, CFO.

To participate in the teleconference, please use the following link and telephone numbers:

http://cloud.magneetto.com/wonderland/2016_0607_Financial_Hearing_Probi/view

From Sweden: +46 8 566 426 90
From the UK: +44 203 008 98 04
From the US: +1 855 753 22 35

FOR FURTHER INFORMATION, CONTACT:
Peter Nählstedt, CEO, Probi, tel +46 46 286 89 23 or mobile +46 723 86 99 83, e-mail: peter.nahlstedt@probi.se
Niklas Brandt, CFO, Probi, tel +46 46 286 89 26 or mobile +46 706 62 98 83, e-mail: niklas.brandt@probi.se

ABOUT PROBI
Probi AB is a Swedish publicly traded bioengineering company that develops effective and well-documented probiotics. Through its world-leading research, Probi has created a strong product portfolio in the gastrointestinal health and immune system niches. Probi’s products are available to consumers in more than 30 countries worldwide. Probi’s customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. In 2015 Probi had sales of MSEK 216. The Probi share is listed on Nasdaq Stockholm, Small Cap. Probi has about 4000 shareholders. Read more at www.probi.se .

Tags:

About Us

Probi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas. The products are available to consumers in more than 40 countries worldwide. The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. The Probi share is listed on NASDAQ OMX Stockholm, Mid-cap. Read more on www.probi.se.

Contacts

Subscribe

Documents & Links